A new biomarker for detecting upper motor neuron issues in ALS patients
Intermuscular coherence: A novel biomarker for upper motor neuron dysfunction in ALS
This study is looking at a new way to check how well your nerves and muscles are working in people with ALS, using a quick and easy test that could help doctors better understand your condition and track how it's changing over time.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10994131 on NIH RePORTER |
What this research studies
This research investigates a potential biomarker called intermuscular coherence (IMC) that could help in diagnosing upper motor neuron dysfunction in patients with amyotrophic lateral sclerosis (ALS). The study will involve multiple centers and aims to validate IMC as a reliable measure of motor neuron health by comparing muscle activity patterns in ALS patients to those in healthy individuals. The measurement process is quick, non-invasive, and can be performed using standard clinical equipment, making it accessible for routine use. If successful, this research could significantly enhance the ability to monitor ALS progression and treatment response.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with amyotrophic lateral sclerosis (ALS) who are experiencing symptoms related to upper motor neuron dysfunction.
Not a fit: Patients with other neurological conditions that do not involve upper motor neuron dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, reliable method for early diagnosis and monitoring of ALS, potentially leading to better patient management and treatment outcomes.
How similar studies have performed: Previous studies have shown promising results with similar biomarker approaches in other neurodegenerative diseases, suggesting potential for success in this novel application.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Rezania, Kourosh — University of Chicago
- Study coordinator: Rezania, Kourosh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.